| 23rd week of 2009 patent applcation highlights part 34 |
| Patent application number | Title | Published |
|---|
| 20090142307 | Shape-Based Approach for Scaffoldless Tissue Engineering - Methods for forming tissue engineered constructs without the use of scaffolds and associated methods of use in tissue replacement. One example of a method may comprise providing a shaped hydrogel negative mold; seeding the mold with cells; allowing the cells to self-assemble in the mold to form a tissue engineered construct. | 2009-06-04 |
| 20090142308 | Methods for treating autoimmune disease by inducing autoantigen-specific regulatory CD4+ T cells - Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual β-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention. | 2009-06-04 |
| 20090142309 | Hydroxyphenyl cross-linked macromolecular network and applications thereof - A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are described. In an embodiment, the network is composed of tyramine-substituted and cross-linked hyaluronan molecules, wherein cross-linking is achieved via peroxidase-mediated dityramine-linkages that can be performed in vivo. The dityramine bonds provide a stable, coherent hyaluronan-based hydrogel with desired physical properties. | 2009-06-04 |
| 20090142310 | METHOD OF TREATING INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDES - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. | 2009-06-04 |
| 20090142311 | ENGINEERED INTERVERTEBRAL DISC TISSUE - Surgically implantable tissue engineered intervertebral disc tissues that effectively replicate the physicochemical properties of the corresponding in vivo tissues are provided. Methods for producing such tissues can involve culturing the intervertebral disc cells to produce cells surrounded by an extracellular matrix and culturing the cells and matrix on a semipermeable membrane to form a cohesive tissue. | 2009-06-04 |
| 20090142312 | Methods for Promoting Wound Healing and Muscle Regeneration with the Cell Signaling Protein Nell1 - The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule. | 2009-06-04 |
| 20090142313 | VAGINAL DELIVERY SYSTEM - The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments, one of each comprising a core and a membrane encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone ant at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance. | 2009-06-04 |
| 20090142314 | MATERNAL SUPPLEMENT - The use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant woman for reducing the risk of development of overweight or obesity of the baby in infancy and/or early childhood. | 2009-06-04 |
| 20090142315 | Methods for the Dietary Management of Irritable Bowel Syndrome and Carbohydrate Malabsorption - The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a | 2009-06-04 |
| 20090142316 | Use of Dendrimers to Stimulate Cell Growth - The present invention relates to the use of dendrimers with monophosphonic or bisphosphonic terminations in order to stimulate the growth of cell cultures or to activate cells in culture. | 2009-06-04 |
| 20090142317 | PROCESS FOR REDUCING EFFECTS OF GRAFT VERSUS HOST DISEASE USING EX VIVO EXPANDED CD4+CD25+ REGULATORY T CELLS - Disclosed in this specification is a process for producing ex vivo expanded CD4+CD25+ regulatory T cells. The process includes the steps of extracting a sample that includes peripheral blood mononuclear cells from a human donor. The extracted cells include a certain number of cells which are CD4+CD25+ regulatory T cells. The relative population of the CD4+CD25+ regulatory T cells is enhanced such that the Treg cells constitute the majority of the cells in the sample. Thereafter, the population of the enriched Treg cells, that may include third-party derived Treg cells, is expanded to produce a clinically meaningful population of cells for use in the treatment of GVHD. | 2009-06-04 |
| 20090142318 | METHOD TO EXPAND nTREG CELLS USING p70 S6 KINASE ANTAGONIST - Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while treating the culture with a p70 S6 kinase inhibitor. The resulting cells are useful in the treatment of immune-related diseases. | 2009-06-04 |
| 20090142319 | METHOD TO EXPAND nTREG CELLS USING PI-3K ANTAGONIST - Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while treating with a PI-3K antagonist. The resulting cells are useful in the treatment of immune-related diseases. | 2009-06-04 |
| 20090142320 | METHOD TO MINIMIZE IL-17 PRODUCTION DURING nTREG CELL EXPANSION - Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while minimizing the production of IL-17. The resulting cells are useful in the treatment of immune-related diseases. | 2009-06-04 |
| 20090142321 | Opthalmic composition - An ophthalmic composition which is prepared by incorporating pyridoxine hydrochloride in combination with chondroitin sulfate and a cellulosic polymer. The composition is reduced or eliminated in eye irritation attributable to pyridoxine hydrochloride. | 2009-06-04 |
| 20090142322 | Coenzyme Q10 Production in a Recombinant Oleaginous Yeast - Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of co-producing coenzyme Q | 2009-06-04 |
| 20090142323 | METHODS FOR TREATING A DISORDER BY REGULATING GPRC6A - A disorder related to a non-genomic androgen response or a metabolic syndrome can be treated, inhibited, and/or prevented by regulating an expression level and/or activity of GPRC6A. Such a method can include identifying an individual with a disorder associated with a non-genomic androgen response or metabolic syndrome; and administering to the individual in need thereof an agent capable of regulating an expression level and/or activity of GPRC6A thereby treating the disorder associated with the non-genomic androgen response or metabolic syndrome. The regulation of GPRC6A can increase or decrease the concentration of a sex hormone within said individual, as needed for a particular disease. Such regulating can also be used to treat, inhibit, or prevent the symptoms of such a disease. | 2009-06-04 |
| 20090142324 | OIL-IN-WATER TYPE EMULSION CONTAINING COENZYME Q10 AND PROCESS FOR PRODUCING THE SAME - To provide an oil-in-water emulsion composition that prevents separation of coenzyme Q | 2009-06-04 |
| 20090142325 | COMPOSITIONS AND METHODS FOR TREATING TUMOUR SPREADING - There is provided a method of prevention or inhibition of uncontrolled proliferation of a cancer comprising administration to a mammal of a therapeutically effective amount of a pharmaceutical composition comprising a cell-permeable fusion protein conjugate comprising a polypeptidic cell-membrane transport moiety and a | 2009-06-04 |
| 20090142326 | Glycosidase Enzymes - A thermostable glycosidase enzymes derived from various | 2009-06-04 |
| 20090142327 | Novel Class of Therapeutic Protein Based Molecules - The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy. | 2009-06-04 |
| 20090142328 | Uses of antileukoprotease in carcinoma - The present invention provides a method of detecting/monitoring tumor growth and progression in a tissue by measuring the level of antileukoprotease. Also provided is a method of treating an individual having a tumor by administering antileukoprotease to inhibit the activity of stratum corneum chymotryptic enzyme. Specifically, the tumor is an ovarian carcinoma. | 2009-06-04 |
| 20090142329 | Interleukin-1 Beta Converting Enzyme Like Apoptosis Protease-3 and 4 - Disclosed are human interleukin-1 β converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor agent, and antiviral agent, and antibodies and antagonists against such polypeptides for example, for treating Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and head injury. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed. | 2009-06-04 |
| 20090142330 | Use of inactive-plasmin to treat chronic inflammatory disease and tumors - Methods are provided for the suppression of inflammation or a tumor. The methods can include selecting a subject in need of suppression of inflammation or the tumor and inhibiting plasmin activity in the subject to decrease matrix metalloproteinase production, thereby suppressing the inflammation or tumor. In several examples, an agent including inactive plasmin at a therapeutically effective concentration is administered to inhibit plasmin activity. Methods are also provided for modulating annexin A2 receptor activity. | 2009-06-04 |
| 20090142331 | Method for the Production of Bio-Active Substances from the Novel Actinomycete TAXA MAR3A, MAR3B And MAR4 Belonging to the Family Treptomycetaceae - This invention provides a method for the isolation and identification of marine actinomycetes tentatively named MAR3A and MAR3B and the use of these groups as a source of new biologically active compositions including pharmaceuticals. The method includes specifics about where these microorganisms occur and their culture requirements. It also provides information describing characteristic DNA sequences that are used to identify members of this group and information demonstrating that members produce metabolites with significant activities in pharmaceutically relevant bioassays. | 2009-06-04 |
| 20090142332 | Identification of Biomarkers by Serum Protein Profiling - The present invention relates to methods of determining colorectal cancer status in a subject. The invention further relates to kits for determining colorectal cancer status in a subject. The invention further related to methods of identifying biomarker for determining colorectal cancer status in a subject. | 2009-06-04 |
| 20090142333 | Activin-actriia antagonists and uses for promoting bone growth in cancer patients - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. | 2009-06-04 |
| 20090142334 | DETECTION AND MODULATION OF IAPs AND NAIP FOR THE DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISEASE - Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids, IAP fragments, and antibodies which specifically bind IAP polypeptides. | 2009-06-04 |
| 20090142335 | Methods of diagnosis and treatment of metabolic disorders - The invention features diagnostic methods for metabolic disorders (e.g., diabetes and obesity), methods for screening for compounds useful in the treatment of metabolic disorders, and methods for treatment of metabolic disorders that involve sirtuin2. | 2009-06-04 |
| 20090142336 | METABOLIC REGULATORS AND USES THEREOF - The present invention relates to metabolic regulators that affect metabolic function, for example metabolic regulators that affect muscle mass, muscle regeneration, muscle hypertrophy, fat mass, insulin and glucose sensitivity, angiogenesis and cardiovascular function. In particular, the present invention relates to modulating metabolic function by administering an effective amount of a pharmaceutical composition comprising an agent, where the agent activates or inhibits the activity and/or gene expression of the metabolic regulator. The metabolic regulators of the present invention are, for example MSP1 (2160028F08Rik; SEQ ID NO: 16); MSP2 (2310043I08Rik; SEQ ID NO: 17); MSP3 (NM_026754;1 110017116Rik; SEQ ID NO: 1); MSP4 (4732466D17Rik; SEQ BD NO: 18); MSP 5 (NM_024237; 1600015H20Rik; SEQ ID NO: 12); Ins16 (AF_156094; SEQ ID NO: 20). The present invention also provides methods to screen for agents that affect the metabolic regulators of the present invention. | 2009-06-04 |
| 20090142337 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment - The invention provides a combination comprising (or consisting essentially of) an ancillary compound and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein: R | 2009-06-04 |
| 20090142338 | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions - Embodiments of the present invention relate to compositions and methods of treating type 1 or type 2 diabetes mellitus or other conditions relating to metabolic dysfunction that may impact insulin secretion or action by administering an islet neogenesis agent in combination with an agent or agents that selectively inhibits, blocks or destroys the autoimmune destruction of pancreatic cells or agents that optimize function within existing islets in patients with type 1 diabetes, type 2 diabetes and related conditions. | 2009-06-04 |
| 20090142339 | Humanized Anti-CCR2 Antibodies and Methods of Use Therefor - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods. | 2009-06-04 |
| 20090142340 | Optimized Fc Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 2009-06-04 |
| 20090142341 | Mutated pseudomonas exotoxins with reduced antigenicity - The invention provides mutated | 2009-06-04 |
| 20090142342 | B7-H4 RECEPTOR AGONIST COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND AUTO-IMMUNE DISEASES - Compositions containing B7-H4 receptor agonists in an amount effective to reduce, inhibit, or mitigate an inflammatory response in an individual and methods for the treatment or prophylaxis of inflammatory disorders and autoimmune diseases or disorders have been developed. It has been discovered that B7-H4 receptor agonists, for example B7-H4 fusion proteins function as an agonist of the B7-H4 receptor on T cells to suppress both humoral and cellular autoimmunity activity. In one embodiment, B7-H4 fusion proteins compete with sH4 for a common receptor on T cells. | 2009-06-04 |
| 20090142343 | Anti-VEGF antibodies - The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies. | 2009-06-04 |
| 20090142344 | BREAST CANCER RELATED GENE ZNFN3A1 - Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. Also described are methods of treating and preventing breast cancer and breast cancer metastasis as well as methods of assessing the prognosis of a breast cancer subject and the efficacy of a breast cancer therapy. In one embodiment, the diagnostic method involves determining the expression level of ZNFN3A1, a gene whose expression is markedly elevated in breast cancers, that therefore can be used to discriminate between BRC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of BRC, methods of treating BRC and method for vaccinating a subject against BRC. | 2009-06-04 |
| 20090142345 | PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER - The present invention provides a safe drug that targets a molecule specifically expressed in cancer cells, and that induces cancer cell growth inhibition. More specifically, the present invention provides a neutralizing antibody against a protein comprising the same or substantially the same amino acid sequence as that shown by SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO:9, or a partial peptide thereof or a salt thereof, and a prophylactic/therapeutic agent for cancers (for example, breast cancer, ovarian cancer, colorectal cancer, lung cancer, pancreatic cancer) and the like, apoptosis promoter, cancer cell growth suppressant, DDR1 antagonist and the like, comprising the neutralizing antibody. | 2009-06-04 |
| 20090142346 | Preventive/Remedy for Cancer - A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an apoptosis inducer of cancer cells, a growth inhibitor of cancer cells, a cytotoxic agent against cancer cells through a host defense mechanism mediated by the Fc region of an antibody, and so on. | 2009-06-04 |
| 20090142347 | Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification - This invention relates generally to the field of mineralization, and specifically to the role of TNAP in regulating the levels of extracellular inorganic pyrophosphate. The invention provides methods for modulating the activity of TNAP activity; methods for screening for modulators of TNAP activity; modulators of TNAP activity; and methods for treating pathologic conditions known of suspected to be affected by modulation of TNAP activity. | 2009-06-04 |
| 20090142348 | Novel Gene Disruptions, Compositions and Methods Relating Thereto - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO844, PRO1131 or PRO5992 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. | 2009-06-04 |
| 20090142349 | CD19 Antibodies And Their uses - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed. | 2009-06-04 |
| 20090142350 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 2009-06-04 |
| 20090142351 | Human and rat PGC-3, PPAR-gamma coactivations and splice variants thereof - A novel gene PGC-3, and its role in regulating the transcriptional activity of PPARγ in adipose tissue. PGC-3 is highly expressed in human white adipose tissue and has utility in the development of new therapeutic agents for use in the treatment of obesity and other related disorders such as non-insulin dependent diabetes mellitus, insulin resistance syndrome, dyslipidemia, and atherosclerosis. | 2009-06-04 |
| 20090142352 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 2009-06-04 |
| 20090142353 | Human Tumor Necrosis Factor Receptor TR17 - The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for producing the same. The invention further relates to methods of killing cells using the antibodies of the invention. | 2009-06-04 |
| 20090142354 | HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds dimeric hDll4 with an affinity of 75 pM or better, as measured by surface plasmon resonance. | 2009-06-04 |
| 20090142355 | DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES - Methods for the diagnosis and treatment of type 1 diabetes are described. HLA-DQA2 has now been identified as the gene which is primarily responsible for determining whether an individual is susceptible to develop type 1 diabetes. The use of HLA-DQA2 as a target for developing therapeutic and diagnostic targets for treating type 1 diabetes and detecting susceptibility for the disease is disclosed. | 2009-06-04 |
| 20090142356 | Pharmaceutical Composition of F(ab')2 Antibody Fragments and a Process for the Preparation Thereof - The present invention is directed to a pharmaceutical composition comprising F(ab′) | 2009-06-04 |
| 20090142357 | Specific Depletion of CD4+ T Cells - Specific depletion or modulation of activity of CD4 | 2009-06-04 |
| 20090142358 | HUMAN ANTIBODIES SPECIFIC TO KDR AND USES THEREOF - The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal. | 2009-06-04 |
| 20090142359 | Antibody-induced apoptosis - Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions. | 2009-06-04 |
| 20090142360 | USE OF FERRITIN TO TREAT IRON DEFICIENCY DISORDERS - The present inventors have demonstrated the presence of H-ferritin receptors on endothelial cells in culture and on rat brain rat brain microvasculature, identifying H-ferritin as a means for transporting iron across the blood brain barrier. The present invention provides a method for treating an iron deficiency disorder in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a ferritin-iron complex. In an embodiment of the invention, the ferritin-iron complex comprises H-ferritin. In another embodiment, the iron deficiency disorder comprises an iron deficiency in the brain. The present invention also provides a method for delivering iron to the brain, comprising administering iron in the form of a ferritin-iron complex to a patient, whereby said iron is transported across the blood-brain barrier and delivered to the brain; a method for using H-ferritin as a targeting moiety, comprising attaching H-ferritin to a liposome, whereby said liposome is targeted to the brain and/or cells within the brain; and a method for treating an iron overload disorder in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a multi subunit ferritin complex, wherein said multi subunit ferritin complex is at less than 100% iron binding capacity. | 2009-06-04 |
| 20090142361 | DRUG CONJUGATE COMPOSITION - The invention provides a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human the reconstituted composition such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed. | 2009-06-04 |
| 20090142362 | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) - Improved vaccine compositions and methods of use thereof are described that elicit production of antibodies in an individual to the individual's own endogenous cholesteryl ester transfer protein (CETP). | 2009-06-04 |
| 20090142363 | CYTOTOXIC T-CELL EPITOPE PEPTIDE AND USE THEREOF - The successful identification of epitope peptides specific to adenovirus belonging to subgroup B and epitope peptides exhibiting specificity to all adenoviruses using hexon proteins which exhibit the highest homology among genes of adenoviruses of various subgroups is herein described. The peptides have a function capable of efficiently inducing adenovirus-specific cytotoxic T cells (CTLs). Thus, the peptides disclosed herein find utility as vaccines for active immunization. Furthermore, CTLs induced by such peptides find utility as passive immunotherapeutic agents. | 2009-06-04 |
| 20090142364 | Method for finding novel peptide immunostimulatory adjuvants, compositions and methods of use - The invention describes production of an adjuvant with biological activities related to N-acetylglucosaminyl-β1-4-N-acetylmuramyl-alanyl-D-isoglutamine (GMDP), a commonly used enhancer of the immune response. It was found in the present invention that the drawbacks of GMDP can be avoided by replacing it with a peptide that does not have any direct structural relationship with GMDP. | 2009-06-04 |
| 20090142365 | COMPOSITIONS AND METHODS FOR USING CA9 PROTEIN TO STIMULATE AN IMMUNE RESPONSE - Provided are methods for stimulating an immune response to an antigen by administering a composition to an individual in an amount effective to stimulate an immune response to the antigen. The stimulated immune response to the antigen is greater than the immune response stimulated by the antigen in the absence of CA9 protein. The compositions provided contain a complex that includes an antigen and an isolated CA9 protein. | 2009-06-04 |
| 20090142366 | Yeast-Based Vaccines As Immunotherapy - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 2009-06-04 |
| 20090142367 | Yeast-Based Vaccines As Immunotherapy - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 2009-06-04 |
| 20090142368 | Chemically Programmable Immunity - The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in a human or animal that has been preimmunized against the first binding site, and (2) one or more second binding sites that bind specifically to a desired compound or molecule. The first binding site and the second binding site(s) are linked by a linker portion of the molecule. | 2009-06-04 |
| 20090142369 | Method for preventing skin-cellular injury by using green algae extract and cosmetic composition containing green algae extract - A method for preventing UV-induced skin-cellular injury by using a green algae extract and a cosmetic composition containing the green algae extract are disclosed. An effective dose of the green algae extract is used to protect fibroblasts from UV-induced apoptosis. The mechanism of the disclosed method is using the green algae extract to inhibit interaction between apoptosis pathway molecules Fas/FasL so as to inhibit an adapter protein (FADD) in a death-inducing signaling complex (DISC) and in turn to inhibit caspase-3 activation and cleaved polymerase (PARP) such that irreparable damage to DNA can be prevented. The green algae extract can be mixed with a skin permeable cosmetic composition so that the cosmetic composition possesses the function of preventing skin from UV-induced injury. | 2009-06-04 |
| 20090142370 | Method for preventing skin-cellular aging by using green algae extract and cosmetic composition containing green algae extract - A method for preventing skin-cellular aging by using a green algae extract and a cosmetic composition containing the green algae extract are disclosed. An effective dose of the green algae extract is used to inhibit the activity of Metalloproteinase (MMP) in the fibroblast and to promote of collagens and elastins production in the fibroblast. The green algae extract can be mixed with a skin permeable cosmetic composition so that the cosmetic composition performs the effect of preventing extrinsic skin aging. | 2009-06-04 |
| 20090142371 | HIV RECOMBINANT VACCINE - Reagents and methods for making and using HIV recombinant vaccines are disclosed. | 2009-06-04 |
| 20090142372 | Therapeutic composition for use in the prevention and treatment of bone metastases - The invention is relates to drugs on the basis of antibodies against non-cellular bone matrix proteins, especially BSP, for use in the prevention and treatment of bone metastases. According to the invention, the antibodies are induced in the patient by recombinantly expressing antigenic determinants of bone matrix proteins in | 2009-06-04 |
| 20090142373 | Immunizing Against HIV Infection - A virus neutralizing level of antibodies to a primary HIV isolate is generated in a host by a prime-boost administration of antigents. The primary antigen is a DNA molecule encoding an envelop glycoprotein of a primary isolate of HIV-1 while the boosting antigen is either a non-infectious, non-replicating HIV-like particle having the envelope glycoprotein of a primary isolate of HIV-1 or an attenuated viral vector expressing an envelope glycoprotein of a primary isolate of HIV-1. | 2009-06-04 |
| 20090142374 | COMPOSITION FOR IMMUNOSTIMULATION - The present invention relates to a composition for immunostimulation useful for promoting IgA and secretory component productions in mucosal tissues, comprising, alone or in combination, a cell of bifidobacterium belonging to | 2009-06-04 |
| 20090142375 | LIPOTEICHOIC ACID FROM LACTIC ACID BACTERIA AND ITS USE TO MODULATE IMMUNE RESPONSES MADIATED BY GRAM-NEGATIVE BACTERIA, POTENTIAL PATHOGENIC GRAM-POSITIVE BACTERIA - The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and/or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as an active ingredient and/or lactic acid bacteria producing it and/or its supernatant of culture, in the manufacture of a medicament, an oral or topical product for cosmetic, dermatological or ophtalmological applications, a food or petfood composition for modulating bacterial colonisation, immune responses and decreasing the inflammatory processes associated with bacterially-mediated disease and infection in the gastrointestinal tract, bone, skin, eye, ear, lung and oral cavity. The invention also relates to lipoteichoic acid selected thereof. | 2009-06-04 |
| 20090142376 | CHLAMYDIA POLYPEPTIDES AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF - The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of | 2009-06-04 |
| 20090142377 | Immunogenic compositions - Described are means and methods for producing and/or selecting immunogenic compositions, comprising providing the composition with at least one cross-beta structure and testing at least one immunogenic property. | 2009-06-04 |
| 20090142378 | CONTROLLED RELEASE DOSAGE FORMS - The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups. | 2009-06-04 |
| 20090142379 | Coated Products Containing Hydrogenated Indigestible Starch Syrup as a Binding Agent - An object of the present invention is to provide a coated product with increased stiffness to reduce the chipping after manufacturing and several days of storage, and before wrapping. A coated product such as confectioneries such as chewing gum, medicines and medicinal tablets wherein the product is coated with a coating composition comprising hydrogenated indigestible starch syrup as a binding agent. | 2009-06-04 |
| 20090142380 | COSMETIC COMPOSITION IN POWDERED FORM - Disclosed herein is an anhydrous cosmetic composition in powdered form comprising at least one pulverulent phase and at least one fatty binder, the said pulverulent phase comprising i) 30 to 70% by weight, relative to the total weight of the composition, of at least one pigment, and ii) 30 to 70% by weight, relative to the total weight of the composition, of at least one lamellar particle. Disclosed herein is also a method for making up the skin, comprising applying the composition to the skin, and a method for concealing the color defects of the skin, while conferring a natural and satiny appearance on the made-up skin. | 2009-06-04 |
| 20090142381 | LAMELLAR OIL-IN-GLYCOL GEL COMPOSITIONS AND THE PROCESS OF PREPARATION - The present invention is directed to a lamellar oil-in-glycol gel comprising (a) at least one glycol, (b) at least one fatty alcohol, (c) at least one cationic surfactant and optionally (d) at least one benefit agent, said lamellar gel capable of providing enhanced mass and promoting the permeation of the benefit agent through a keratinous substrate such as the skin, hair and fingernails, providing both deep and superficial treatment thereof. | 2009-06-04 |
| 20090142382 | Powder Cosmetic Composition - Methods for preparing a solid powder cosmetic composition comprise heating a wax component and one or more cosmetic powders at a temperature sufficient to melt the wax, and subsequently cooling the mixture to provide a solid composition comprising a wax matrix having particulate materials homogenously dispersed therein. | 2009-06-04 |
| 20090142383 | O/W EMULSION COSMETIC COMPOSITION - Provided is an O/W emulsion cosmetic composition, which contains the following components (A), (B) and (C):
| 2009-06-04 |
| 20090142384 | Viscoelastic material - The invention relates to a tough-elastic material based on starch, which on the one hand has high impact toughness at low humidities, and on the other hand still has a high modulus of elasticity at high humidities and has a high elongation capacity in a broad range of humidities and on account of its property profile is suited to use as molded elements such as for example for foils, films, fibers, injection-molded articles, in particular as edible film and for the packaging of active ingredients, chemicals, aromas and perfumes as well as high-quality substitution of gelatine in the area of soft and hard capsules. The tough-elastic material can be obtained transparent and adjusted such that it dissolves on swelling in water or respectively disintegrates or remains intact. | 2009-06-04 |
| 20090142385 | COMPOSITIONS FOR TREATING BONE DEFECTS - In certain described embodiments, implantable medical materials comprise a scaffolding material, a liquid organic binder, and entrapped calcium-containing particles. The medical materials can incorporate an osteoinductive factor such as a protein. The scaffolding material can bind the factor. In additional described embodiments, implantable medical materials include an osteoconductive scaffolding material, an incorporated osteoinductive factor, and a biodegradable barrier material effective to delay release of the factor from the scaffolding material. The scaffolding material can bind the factor. Also described a methods for preparing and implanting the described medical materials. | 2009-06-04 |
| 20090142386 | CONTROL OF DRUG RELEASE BY TRANSIENT MODIFICATION OF LOCAL MICROENVIRONMENTS - Methods, formulations, and devices are provided for enhancing drug delivery from a medical device. The method is provided for increasing the rate or quantity of a drug formulation released from an implantable drug delivery device, which method comprises the step of providing a release-modifying agent within or proximate to the implantable drug delivery device, in a manner effective to inhibit gelation, aggregation, or precipitation of the drug formulation being released from the device. The drug formulation and the release-modifying agent may be stored together in at least one reservoir in the implantable drug deliver device. Alternatively, the release-modifying agent may be stored in one or more reservoirs separate from the drug formulation. | 2009-06-04 |
| 20090142387 | Method For Inhibiting Attachment Of Microorganisms To Biomedical Devices - A method for inhibiting adhesion of bacteria to a surface of a biomedical device is disclosed. The method involves at least (a) incorporating one or more non-functionalized polymers having one or more hydrophilic moieties into an ophthalmic device that is a polymerization product of a comonomer mixture comprising: (i) a major amount of a non-silicone-containing hydrophilic monomer; and (ii) an end-terminal functionalized surfactant; and (b) inserting the ophthalmic device in the eye of a patient, wherein the at least one non-functionalized polymer migrates to the surface of the device in a sustained release manner to inhibit adhesion of bacteria to a surface of the biomedical device. Biomedical devices are also disclosed. | 2009-06-04 |
| 20090142388 | Patch preparation - The present invention aims at provision of a patch preparation having a small area and permitting adhesion for a long time. | 2009-06-04 |
| 20090142389 | HYDROGEL SHEET AND PRODUCTION METHOD THEREOF - Provided is a hydrogel sheet being excellent in strength and flexibility and having high water content in spite of comprising a smaller amount of polymer material; and a method for producing a hydrogel sheet which is convenient and has high productivity. More specifically, provided is a hydrogel sheet comprising (methyl vinyl ether/maleic acid) crosspolymer, low-substituted cellulose ether and water wherein the low-substituted cellulose ether has a molar substitution degree of | 2009-06-04 |
| 20090142390 | TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY - A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. | 2009-06-04 |
| 20090142391 | Conjugated RNAi Therapeutics - A method for modulating at least one pharmacokinetic property of a drug which degrades mRNA upon administration to a host by an siRNA mechanism is provided. In a further embodiment of this invention, a bifunctional compound comprising an siRNA and a recruiter moiety are provided. The recruiter moiety may be lipophilic and may enable the siRNA to cross cell membranes and then targets an endogenous, intracellular protein to allow better distribution of the therapeutic into the cell and therefore, higher efficacy. | 2009-06-04 |
| 20090142392 | Composition Comprising a NSAID and Paracetamol - A process for producing a granular composition comprising a plurality of solidified melt granules including a non-steroidal anti-inflammatory drug (NSAID) and paracetamol (acetaminophen), the process comprising the steps of: (a) forming a melt mixture by mixing a molten NSAID free acid and paracetamol, optionally with one or more excipients; and (b) forming the melt mixture into solidified melt granules. The granules are useable in compositions for treating pain and/or inflammation and/or fever. | 2009-06-04 |
| 20090142393 | Stable Compositions of Famotidine and Ibuprofen - Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine. | 2009-06-04 |
| 20090142394 | Gastric Antacid - A novel particulate composite hydrotalcite which offers antacidic effect comparable to that of a particulate hydrotalcite so far used as a gastric antacid and, further, offers excellent stomach inner wall protection effect. A particulate composite hydrotalcite represented by the following formula (1), | 2009-06-04 |
| 20090142395 | DEFERASIROX PHARMACEUTICAL COMPOSITIONS - The present invention provides a process of preparing a high-load formulation of deferasirox with a sufficiently high dissolution rate and good bioavailability, which reduces the effect of the active material's physical characteristics on the chemical and physical properties of the final product. | 2009-06-04 |
| 20090142396 | USE OF A REGENERATIVE BIOFUNCTIONAL COLLAGEN BIOMATRIX FOR TREATING VISCERAL OR PARIETAL DEFECTS - Techniques for treating visceral or parietal membrane and tissue defects include the application of a collagen biomatrix to the defect to repair and regenerate a visceral or parietal membrane, for example in patients suffering tissue defects or undergoing visceral or parietal surgical treatment. Such approaches avoid persistent tissue leaks and their consequences such as fluid leaks and air leaks. The use of collagen biomatrix, optionally in conjunction with a fibrin sealant, an anti-adhesive, or both, can minimize tissue leaks or fluid leaks in injured patients suffering tissue defects or subjects undergoing surgery such as visceral or parietal resections and other operations. | 2009-06-04 |
| 20090142397 | REDUCTION OF DERMAL SCARRING - Methods and compositions for reducing or inhibiting dermal scarring by expressing p21 | 2009-06-04 |
| 20090142398 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING A DISINTEGRATION MATRIX - The present invention relates to a stable pharmaceutical composition comprising a pharmaceutically active substance having poor water solubility dispersed in a pharmaceutically acceptable disintegration matrix, said disintegration matrix comprising at least one pharmaceutically acceptable disintegrant, a pharmaceutically acceptable basic agent provided in a molar ratio of basic agent to active substance of 1:1 to 10:1, a water-insoluble pharmaceutically acceptable diluent, optionally, if desired or necessary at least one pharmaceutically acceptable excipients and/or pharmaceutically acceptable adjuvants, and optionally a pharmaceutically acceptable surfactant or emulsifier. The present invention also provides a process to make such. | 2009-06-04 |
| 20090142399 | DISPERSANT AGENT FOR SUSTAINED-RELEASE PREPARATIONS - The present invention provides a bilayer dispersing agent for a sustained-release preparation, which contains a non water-soluble solvent and an aqueous solvent, and a sustained-release preparation wherein a microcapsule containing a physiologically active substance is dispersed in the aforementioned dispersing agent. When this preparation is subcutaneously administered, the initial release of a physiologically active substance immediately after administration is strikingly suppressed, a constant amount of a physiologically active substance is released for a long period of time from immediately after administration, superior dispersibility is afforded, and the preparation can readily pass through a needle as an injection. | 2009-06-04 |
| 20090142400 | ANALGESIC COATED MEDICAL PRODUCT - Described are medical products including an analgesic such as lidocaine, bupivicaine, or a mixture thereof. Such medical products can find use in pain relief, particularly after surgery, and can be applied to tissue or can be implanted within a patient. Also described are medical products including an extracellular matrix material, one or more analgesic agents, and a carrier effective to extend the release of the agent(s). Related methods of manufacture and use are also described. | 2009-06-04 |
| 20090142401 | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release - Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed. | 2009-06-04 |
| 20090142402 | MICROPARTICLES, MICROPARTICLE DISPERSION AND METHOD AND APPARATUS FOR PRODUCING THE SAME - A method and an apparatus enabling manufacture of a microparticle dispersion liquid at high efficiency in a short time while suppressing drug degradation, etc., are provided. In a dissolving step, a poorly soluble drug and a dispersion stabilizer are dissolved in a volatile organic solvent in a container | 2009-06-04 |
| 20090142403 | ORGAN REGENERATION DEVICE - An organ regeneration device adapted to be used by placing it into a defective portion of an organ to regenerate the organ is provided. The organ regeneration device has a base body having a shape corresponding to a shape of the defective portion of the organ. The organ regeneration device also has particles carried on the base body, wherein the particles are composed of a different material from that of the base body. The organ regeneration device also has a growth-related substance contained in the organ regeneration device for growth and differentiation of cells around the defective portion. The growth-related substance contains an angiogenesis factor. Further, the growth-related substance contains nucleic acid containing a base sequence coding for amino-acid sequence of a growth factor different from the angiogenesis factor. Furthermore, the nucleic acid is introduced into a host cell. | 2009-06-04 |
| 20090142404 | PHARMACEUTICAL DOSAGE FORMS COMPRISING A LOW-SOLUBILITY DRUG AND A POLYMER - A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer. Exemplified low-solubility drugs are ziprasidone and sildenafil. Exemplified precipitation-inhibiting polymer is HPMCAS. | 2009-06-04 |
| 20090142405 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery. | 2009-06-04 |
| 20090142406 | Microencapsulated Pesticide - A microcapsule can be produced easily by (a) pulverizing a solid pesticidal compound in a fatty acid ester represented by formula (I) to form a suspension | 2009-06-04 |
